Tissue Modification After Vit c InjectionNCT07043985
Effect of Vitamin C on Collagen Production in Comparison to Hereditary Gingival Fibromatosis: Histopathological Study
A study testing biopsy in people with Tissue Modification After Vit c Injection, run by Badr University at 1 site in Egypt.
Trial summary
In this preliminary study, we propose that the intraepidermic injection of vit C can induce quantitative and qualitative modification of the gingival biotype. We also propose that such improvement is lacking of any pathologic transformation when will compare to the hereditary gingival fibromatosis with highlighting… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Tissue Modification After Vit c Injection
- What is being tested?
- biopsy
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteEgypt
- Study dates
- 3 Jan 2018to 6 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- patients diagnosed as HGF
- patients diagnosed with altered passive eruption who needs excess gingival tissue removal
- no age or gender predilection
Who cannot join
- patienst undertaken drugs cause gingival enlargment
- prednent and lactating mothers
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Intraepidermic Injection of Vitamin C on Collagen Production Compared to Fibrotic Hereditary Gingival Fibromatosis: Histopathological Study
In this preliminary study, we propose that the intraepidermic injection of vit C can induce quantitative and qualitative modification of the gingival biotype. We also propose that such improvement is lacking of any pathologic transformation when will compare to the hereditary gingival fibromatosis with highlighting the mechanism of fibrous tissue formation. The study aims secondly to provide a detailed explanation for the pathogenesis of HGF.
Read the detailed description
Oral fibromatosis is a benign non-relevant condition that could be an idiopathic solitary manifestation, part of a syndrome or a manifestation associated with systemic disease as leukemia, epilepsy, etc. (Anegundi et al., 2006 and Hakkinen \& Csiszar, 2007). It may be also associated with other minor manifestations as hypertrichosis (Pavone, 2015 and Sabina-Pena-Borges, 2015), anemia, gastro-intestinal disturbance and/ or hormonal disturbance. Up till now, the idiopathic form is a rare condition with no definite hypothesis that could explain its mechanism.
Clinically, the disease usually develop as fibrotic non-painful, pinkish, non-hemorrhagic lesions which can either relate to erupted teeth (deciduous or permanent) or edentulous areas (retromolar region, maxillary tuberosity). The lesions primarily erupt as nodular separate islands related to the interproximal papillae then gradually coalesce (Anegundi et al., 2006; Singhal, 2013 and Gawron et al., 2016).
By the development of such lesions, bad esthetics, speech problems, mastication problems, carious lesions, plaque accumulation are the main complaints of the patients suffer from. Bone loss as well as periodontitis may develop later on as a squeal of plaque accumulation and improper cleaning (Ramer et al., 1996 and Anegundi et al., 2006). The peak of enlargement usually accompanies the beginning of mixed dentition (Anegundi et al., 2006; Singhal, 2013 and Gawron et al., 2016).
According to literature, the genetic susceptibility showed the most reliable explanation to fibromatosis development. It may be transmitted as an autosomal dominant or recessive trait. Local factors also play an important role in disease exacerbation such as plaque, calculus, chemical agents, trauma, restorations, orthodontic appliances, fixed restorations (Anegundi et al., 2006).
Histologically, there is great debate if the enlargement's origin is more relevant to epidermis layer, dermis layer or both. In the epidermal theory, the epithelial layer is the initiating layer due to the epithelial mesenchyme transitions and the presence of keratinocyte growth factor (Boukamp et al., 1990) while in the dermal theory, the overproduction of the dense, fibrous and avascular extracellular matrix with differently oriented collagen bundles, marked reduction in collagenase formation are the initiating factors (Vardar et al., 2005; El-Firt, 2011; Pego et al., 2015). The name fibromatosis is related to the dermal hypothesis due to the over production of fibrous tissues. Finally, the coexistence of epithelial and connective tissue hyperplasia regards to fibroblasts and keratinocytes hyperactivity which supports the third theory (Boukamp et al., 1990).
Away from the pathological conditions, gingival thickness could be intentionally induced to modify the oral tissue biotype using vitamin C (vit C), which has antioxidant and anti-inflammatory properties (Yussif et al., 2016). On microscopic examination, vitamin C tissue modification histologically resembles gingival fibromatosis. Therefore, it is quite important to cautiously examine the biotype modification occurs during vitamin C injection.
Gingival tissue biotype exhibits great clinical significance in preserving the gingival health, determining the treatment outcome and the prognosis of periodontal apparatus (Abraham et al., 2014).
- Being tested
- biopsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
biopsyDiagnostic test
Diagnosis of the HGF and healthy tissues depends on pre-described criteria; gingival overgrowth covering one third of the crown length as a minimum, systemically free, no history of drug uptake causing gingival overgrowth (nifedipine, phenytoin, cyclosporine, oral contraceptive pills). Before sampling, written consents were obtained from all patients. Using light microscope, haematoxylin and eosin (H\&E) stained sections were precisely examined and histopathological features were reported. All specimens were assessed semi-quantitatively, on a graded scale, under ×100 magnification power and a fixed grid for the following parameters. Three to four fields of each gingival specimen were randomly selected. A blinded evaluation was done by two independent observers. If a debate was reported regarding a specimen, a consensus was reached following re-evaluation. The most representative areas were selected to be morphometrically analyzed using Leica QWin 500 analyzer computer system (Germany).
| Study group | Role | What they receive |
|---|---|---|
| G1 (positive control): 5 patients suffering from non-syndromic HGF | Experimental | Gingival bioposy was evaluated Receives: Diagnostic Test: biopsy |
| G2 (negative control): 5 patients of normal healthy gingival tissue (negative control) | Experimental | normal healthy gingival tissue biopsy Receives: Diagnostic Test: biopsy |
| received intraepidermic vitamin C injection for non-inflammatory purpose | Active comparator | vit C injection for non-inflammatory purpose Receives: Diagnostic Test: biopsy |
| G4: 5 patients received vitamin C injection for inflammatory purposes | Active comparator | vitamin C injection for inflammatory purposes Receives: Diagnostic Test: biopsy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area percent occupied by connective tissue
the percent of the tissues occupied by connective tissue only
Measured: 7
Secondary outcomes (1)
Density of Collagen bundles
the percent amount of the collagen bundles
Measured: 7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2025
- Study start3 Jan 2018
- Primary completion5 Nov 2024
- Study completion6 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tissue Modification After Vit c InjectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Badr University
- Sponsor type
- University, hospital or other
- Collaborators
- Cairo University
- Responsible party
- Principal investigator, Rasha Wagih, Badr University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07043985
- Sponsor's protocol ID
- BUC-IACUC-250423-130
- Status last verified
- Jun 2025
- First submitted
- 17 Jun 2025
- Last updated
- 29 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Intraepidermic Injection of Vitamin C on Collagen Production Compared to Fibrotic Hereditary Gingival Fibromatosis: Histopathological Study
- ClinicalTrials.gov ID
- NCT07043985
- Acronym / sponsor ID
- BUC-IACUC-250423-130
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Badr UniversityUniversity, hospital or other
- Collaborators
- Cairo University
- Study start
- 3 Jan 2018 (actual)
- Primary completion
- 5 Nov 2024 (actual)
- Study completion
- 6 May 2025 (actual)
- First posted
- 29 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this preliminary study, we propose that the intraepidermic injection of vit C can induce quantitative and qualitative modification of the gingival biotype. We also propose that such improvement is lacking of any pathologic transformation when will compare to the hereditary gingival fibromatosis with highlighting the mechanism of fibrous tissue formation. The study aims secondly to provide a detailed explanation for the pathogenesis of HGF.
Detailed description
Oral fibromatosis is a benign non-relevant condition that could be an idiopathic solitary manifestation, part of a syndrome or a manifestation associated with systemic disease as leukemia, epilepsy, etc. (Anegundi et al., 2006 and Hakkinen \& Csiszar, 2007). It may be also associated with other minor manifestations as hypertrichosis (Pavone, 2015 and Sabina-Pena-Borges, 2015), anemia, gastro-intestinal disturbance and/ or hormonal disturbance. Up till now, the idiopathic form is a rare condition with no definite hypothesis that could explain its mechanism.
Clinically, the disease usually develop as fibrotic non-painful, pinkish, non-hemorrhagic lesions which can either relate to erupted teeth (deciduous or permanent) or edentulous areas (retromolar region, maxillary tuberosity). The lesions primarily erupt as nodular separate islands related to the interproximal papillae then gradually coalesce (Anegundi et al., 2006; Singhal, 2013 and Gawron et al., 2016).
By the development of such lesions, bad esthetics, speech problems, mastication problems, carious lesions, plaque accumulation are the main complaints of the patients suffer from. Bone loss as well as periodontitis may develop later on as a squeal of plaque accumulation and improper cleaning (Ramer et al., 1996 and Anegundi et al., 2006). The peak of enlargement usually accompanies the beginning of mixed dentition (Anegundi et al., 2006; Singhal, 2013 and Gawron et al., 2016).
According to literature, the genetic susceptibility showed the most reliable explanation to fibromatosis development. It may be transmitted as an autosomal dominant or recessive trait. Local factors also play an important role in disease exacerbation such as plaque, calculus, chemical agents, trauma, restorations, orthodontic appliances, fixed restorations (Anegundi et al., 2006).
Histologically, there is great debate if the enlargement's origin is more relevant to epidermis layer, dermis layer or both. In the epidermal theory, the epithelial layer is the initiating layer due to the epithelial mesenchyme transitions and the presence of keratinocyte growth factor (Boukamp et al., 1990) while in the dermal theory, the overproduction of the dense, fibrous and avascular extracellular matrix with differently oriented collagen bundles, marked reduction in collagenase formation are the initiating factors (Vardar et al., 2005; El-Firt, 2011; Pego et al., 2015). The name fibromatosis is related to the dermal hypothesis due to the over production of fibrous tissues. Finally, the coexistence of epithelial and connective tissue hyperplasia regards to fibroblasts and keratinocytes hyperactivity which supports the third theory (Boukamp et al., 1990).
Away from the pathological conditions, gingival thickness could be intentionally induced to modify the oral tissue biotype using vitamin C (vit C), which has antioxidant and anti-inflammatory properties (Yussif et al., 2016). On microscopic examination, vitamin C tissue modification histologically resembles gingival fibromatosis. Therefore, it is quite important to cautiously examine the biotype modification occurs during vitamin C injection.
Gingival tissue biotype exhibits great clinical significance in preserving the gingival health, determining the treatment outcome and the prognosis of periodontal apparatus (Abraham et al., 2014).
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| G1 (positive control): 5 patients suffering from non-syndromic HGF | Experimental | Diagnostic Test: biopsyGingival bioposy was evaluated |
| G2 (negative control): 5 patients of normal healthy gingival tissue (negative control) | Experimental | Diagnostic Test: biopsynormal healthy gingival tissue biopsy |
| received intraepidermic vitamin C injection for non-inflammatory purpose | Active comparator | Diagnostic Test: biopsyvit C injection for non-inflammatory purpose |
| G4: 5 patients received vitamin C injection for inflammatory purposes | Active comparator | Diagnostic Test: biopsyvitamin C injection for inflammatory purposes |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- patients diagnosed as HGF
- patients diagnosed with altered passive eruption who needs excess gingival tissue removal
- no age or gender predilection
Key exclusion criteria (2 listed)
- patienst undertaken drugs cause gingival enlargment
- prednent and lactating mothers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| biopsyDiagnosis of the HGF and healthy tissues depends on pre-described criteria; gingival overgrowth covering one third of the crown length as a minimum, systemically free, no history of drug uptake causing gingival overgrowth (nifedipine, phenytoin, cyclosporine, oral contraceptive pills). Before sampling, written consents were obtained from all patients. Using light microscope, haematoxylin and eosin (H\&E) stained sections were precisely examined and histopathological features were reported. All specimens were assessed semi-quantitatively, on a graded scale, under ×100 magnification power and a fixed grid for the following parameters. Three to four fields of each gingival specimen were randomly selected. A blinded evaluation was done by two independent observers. If a debate was reported regarding a specimen, a consensus was reached following re-evaluation. The most representative areas were selected to be morphometrically analyzed using Leica QWin 500 analyzer computer system (Germany). | Diagnostic test | G1 (positive control): 5 patients suffering from non-syndromic HGF, G2 (negative control): 5 patients of normal healthy gingival tissue (negative control), G4: 5 patients received vitamin C injection for inflammatory purposes, received intraepidermic vitamin C injection for non-inflammatory purpose |
Primary outcome
Area percent occupied by connective tissue
Time frame: 7
the percent of the tissues occupied by connective tissue only
1 secondary outcome
Density of Collagen bundles
Time frame: 7
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2025.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing biopsy in people with Tissue Modification After Vit c Injection, run by Badr University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area percent occupied by connective tissue (time frame: 7). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2025.